Researchers at the University of Texas MD Anderson Cancer Center published two studies this week on a new approach that could improve treatment for patients with pancreatic cancer. The preclinical studies showed that combining immunotherapy with a KRAS inhibitor can lead to long-lasting tumor elimination.
Polaris Partners-backed XTuit Pharmaceuticals, a cancer-centric biotech that targets therapeutics in the tumor microenvironment, just raised $4 million from three investors – and, according to a regulatory filing, is planning to bring in $6 more. The company was founded in 2011 by Harvard professor Rakesh Jain, MIT chemical engineering professor Bob Langer and Polaris partner Alan […]
As technology advances, AI-powered tools will increasingly reduce the administrative burdens on healthcare providers.